A 32-year-old Indian male presents with a 5-day history of fever (39.5°C), sore throat, and malaise, followed by sudden onset of dusky macules on the trunk and face that have coalesced into flaccid blisters. Nikolsky sign is positive. Oral mucosa shows hemorrhagic erosions. Examination reveals epidermal detachment affecting approximately 22% of body surface area. The patient had started carbamazepine 3 weeks ago for newly diagnosed epilepsy. Based on the classification shown in the diagram marked **D**, which of the following best describes this patient's condition and the most appropriate immediate management?

Explanation

## Why option 1 (SJS-TEN Overlap; immediately discontinue carbamazepine and admit to burns unit for fluid resuscitation and cyclosporine) is right The diagram classification at **D** defines the severity spectrum by body surface area (BSA) of epidermal detachment: SJS <10%, SJS-TEN Overlap 10-30%, and TEN >30%. This patient has 22% BSA involvement, placing him in the SJS-TEN Overlap category (10-30%). Carbamazepine is a well-established high-risk antiepileptic drug for SJS/TEN, particularly in Han Chinese and Indian populations due to HLA-B*1502 association. The clinical presentation—prodrome of fever and sore throat followed by dusky macules, flaccid blisters, positive Nikolsky sign, and mucosal erosions—is pathognomonic for SJS/TEN. Immediate discontinuation of the culprit drug is the single most important intervention and directly reduces mortality. Admission to a burns unit or ICU for fluid resuscitation (LR 3-4 mL/kg/%BSA), thermoregulation, wound care with non-adherent dressings, and cyclosporine (3-5 mg/kg/day × 7-10 days) represents the standard of care. Cyclosporine has the strongest evidence base for reducing mortality in SJS/TEN. [Bolognia Dermatology 5e Ch 21; Harrison 21e Ch 60] ## Why each distractor is wrong - **Option 0 (SJS; continue carbamazepine with supportive care and high-dose corticosteroids)**: This patient has 22% BSA detachment, which falls in the Overlap category (10-30%), not SJS (<10%). More critically, continuing the culprit drug is contraindicated and increases mortality with each day of delay. High-dose corticosteroids initiated after 72 hours have no role and may increase infection risk. - **Option 2 (TEN; continue carbamazepine but initiate IVIG and silver sulfadiazine dressings)**: TEN is defined as >30% BSA detachment; this patient has 22%, placing him in Overlap. Continuing carbamazepine is the most dangerous error—drug withdrawal is the cornerstone of management. Silver sulfadiazine is contraindicated due to sulfa cross-reactivity and risk of exacerbation. IVIG has mixed evidence and is not first-line. - **Option 3 (SJS-TEN Overlap; discontinue carbamazepine and manage with oral antihistamines and topical corticosteroids as outpatient)**: While the classification is correct, outpatient management is inappropriate for SJS-TEN Overlap with 22% BSA detachment. These patients require ICU-level care, fluid resuscitation, thermoregulation, specialized wound care, and systemic immunomodulation. Outpatient management risks death from hypovolemia, sepsis, and ARDS. **High-Yield:** SJS-TEN Overlap (10-30% BSA) requires ICU admission, immediate drug withdrawal, and cyclosporine—not continued drug exposure or outpatient care. [Bolognia Dermatology 5e Ch 21; Harrison 21e Ch 60]